Side effects associated with pneumococcal vaccination

Nichol, Kristin L.; Donald, Roderick Mac; Hauge, Meri

doi:10.1016/s0196-6553(97)90008-0

Cited by 36 publications

(14 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This local reaction rate is similar to that reported for otherwise healthy adults [11], but febrile responses appeared to occur more frequently [29]. One patient who had multiple severe drug allergies was hospitalized, but the patient recovered from a severe acute febrile reaction after reimmunization.…”

Section: Discussionsupporting

confidence: 85%

Reimmunization with 23-Valent Pneumococcal Vaccine for Patients Infected with Human Immunodeficiency Virus Type 1: Clinical, Immunologic, and Virologic Responses

Tasker

Wallace

Rubins

et al. 2002

Clinical Infectious Diseases

View full text Add to dashboard Cite

We determined the immunogenicity and safety of reimmunization with the 23-valent polysaccharide pneumococcal vaccine in patients infected with human immunodeficiency virus type 1 (HIV-1). Patients immunized >5 years earlier (initially within 1 year of HIV-1 seroconversion) were randomized to receive vaccine (n=57) or placebo (n=30). Persons with recent HIV-1 seroconversion (n=14) were immunized for the first time. Preimmunization levels of capsule-specific immunoglobulin G were similar in all groups. Reimmunized patients showed a significantly lower frequency and magnitude of antibody responses compared with persons with recent HIV-1 seroconversion. Reimmunized patients did not show adverse virologic or immunologic changes, but some reported local discomfort (15%) or fever (8%). Thus, the limited responses after reimmunization of HIV-1-infected patients with the current 23-valent vaccine mandates the need for a more effective reimmunization schedule, more immunogenic vaccines, or other behavioral and therapeutic interventions.

show abstract

Section: Discussionsupporting

confidence: 85%

Reimmunization with 23-Valent Pneumococcal Vaccine for Patients Infected with Human Immunodeficiency Virus Type 1: Clinical, Immunologic, and Virologic Responses

Tasker

Wallace

Rubins

et al. 2002

Clinical Infectious Diseases

View full text Add to dashboard Cite

show abstract

“…PPV safety, including that with simultaneous influenza vaccination, has been well documented among older persons (57,95,101,129,144). The primary side effects are local reactions at the injection site.…”

Section: Vaccine Safetymentioning

confidence: 99%

Pneumococcal Vaccination and Revaccination of Older Adults

2003

View full text Add to dashboard Cite

As individuals advance in age, the risk of infection, bacteremia, and mortality caused by Streptococcus pneumoniae rises. Retrospective data demonstrate that the licensed penumococcal polysaccharide vaccine (PPV) is effective in older persons in reducing serotype-specific invasive disease. PPV demonstrates good immunogenicity in older adults, generally comparable to that in younger subjects, although certain cohorts respond less well. The response to PPV is T cell independent, however, and does not elicit immunologic memory. The duration of the anti-capsular polysaccharide antibody response appears to wane as early as 3 years after vaccination. In older persons, revaccination induces an antibody response, although it may not be as strong as that from the initial vaccine. While revaccination of older adults has been recommended, clinical efficacy has not yet been proven. Measures of antibody function may be at least as important in determining protection as are quantitative antibody levels. Additional studies of immunogenicity, particularly regarding revaccination, will facilitate the design of an optimal pneumococcal vaccination policy. Research into conjugate- and protein-based pneumococcal vaccines, which elicit T-cell-dependent responses and induce immunologic memory, is needed in older persons. In the meantime, administering to PPV to recommended groups should be a public health priority

show abstract

“…Un à 8 % des sujets vaccinés contre l'hépatite B présentent des réactions locales importantes, de chronologie souvent accé-lérée [3,37], et les phénomènes d'Arthus sont fréquents lors des injections de rappel des vaccins pneumococciques [40], mais aucun bilan immunoallergologique n'a été effectué chez ces patients.…”

Section: Réactions Localesunclassified

“…À l'exception des réactions inflammatoires locales, le plus souvent bénignes ou modérées, qui sont relativement fréquentes, les injections de vaccins pneumococciques sont généralement bien tolérées. Les quelques phé-nomènes d'Arthus et réactions anaphylactiques rapportés n'ont pas été explorés [40]. Dans une étude récente, les TC à lecture immédiate et un CAP-Rast artisanal ont été positifs chez un enfant rapportant une anaphylaxie grave après la première injection de Pneumo 23 ® .…”

Section: Les Vaccins Pneumococciquesunclassified

Les réactions allergiques et pseudo-allergiques aux vaccins

Ponvert¹

2006

Immuno-analyse & Biologie Spécialisée

View full text Add to dashboard Cite

Side effects associated with pneumococcal vaccination

Cited by 36 publications

References 24 publications

Reimmunization with 23-Valent Pneumococcal Vaccine for Patients Infected with Human Immunodeficiency Virus Type 1: Clinical, Immunologic, and Virologic Responses

Reimmunization with 23-Valent Pneumococcal Vaccine for Patients Infected with Human Immunodeficiency Virus Type 1: Clinical, Immunologic, and Virologic Responses

Pneumococcal Vaccination and Revaccination of Older Adults

Les réactions allergiques et pseudo-allergiques aux vaccins

Contact Info

Product

Resources

About